Skip to content
Reflections of yellow marbles on metal holders
Reflections of yellow marbles on metal holders

Life Sciences

Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.

The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.

We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies – including GlaxoSmithKline, Pfizer, UCB, Merck, Bayer and Novartis.

News & insights

Publications: 30 MARCH 2020

China’s life sciences industry remains opportune despite Covid-19 coronavirus

While the novel Covid-19 coronavirus is at the top of the agenda for businesses around the world, and for good reason, it is creating challenges for medical and healthcare systems and signalling fundamental change across the life sciences industry. 

Read more
coronavirus

Publications: 16 MARCH 2020

Coronavirus - what is the current situation in Germany?

In order to contain the Coronavirus the German federal states as well as the German government have put strict measures into place. Schools and kindergartens have been closed as well as borders to most neighbouring states for private travel. In order to mitigate the economic consequences, the German government announced a comprehensive package of measures.

Read more

Publications: 19 FEBRUARY 2020

Phase One Sino–U.S. trade agreement and the pharmaceutical industry

On 16 January 2020, China and the United States signed the Economic and Trade Agreement between the Government of the People’s Republic of China and the Government of the United States of America (the Phase One Trade Agreement).

Read more

Publications: 04 OCTOBER 2019

Outstanding performance by A&O in global M&A league tables

A&O has marked the end of Q3 2019 with an outstanding performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.

Read more

Recognition

Related links

Life Sciences Hub

We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.

View the blog

CRISPR microsite

The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.

Go to microsite

Growth Capital microsite

Allen & Overy is an engaged and active player in the growth company ecosystem.

Go to microsite

Cannabis microsite

According to UN estimates, the global cannabis market is currently worth approximately USD150 billion annually. 

Go to microsite

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2020

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.

Related content

Global trends in merger control enforcement

Record levels in the first half of 2018 and considerable contraction in the second.